TARS (STOCKS)
Tarsus Pharmaceuticals, Inc. Common Stock
$62.700000
-2.690000 (-4.11%)
Prev close: $65.390000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Bobak Azamian
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,686.82M
- Employees
- 323
- P/E (TTM)
- -31.41
- P/B (TTM)
- 8.28
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
7
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.30 | $-0.36 | +0.0574 | +16.06% |
|
Jun 2025 (Q2)
|
$-0.48 | $-0.41 | -0.0724 | -17.76% |
|
Mar 2025 (Q1)
|
$-0.64 | $-0.75 | +0.1052 | +14.12% |
|
Dec 2024 (Q4)
|
$-0.60 | $-0.76 | +0.1574 | +20.78% |
Financial Statements
| Revenues | $366.10M |
| Benefits Costs and Expenses | $448.50M |
| Costs And Expenses | $453.51M |
| Nonoperating Income/Loss | $6.26M |
| Operating Expenses | $453.51M |
| Selling, General, and Administrative Expenses | $365.67M |
| Research and Development | $63.16M |
| Other Operating Expenses | $24.68M |
| Operating Income/Loss | -$87.41M |
| Income/Loss From Continuing Operations After Tax | -$81.16M |
| Income/Loss From Continuing Operations Before Tax | -$82.40M |
| Net Income/Loss | -$81.16M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$81.16M |
| Net Income/Loss Available To Common Stockholders, Basic | -$81.16M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.99 |
| Diluted Earnings Per Share | -$1.99 |
| Basic Average Shares | 41,774,654 |
| Diluted Average Shares | 41,774,654 |
| Assets | $534.56M |
| Current Assets | $501.70M |
| Inventory | $3.84M |
| Prepaid Expenses | $21.70M |
| Other Current Assets | $476.17M |
| Noncurrent Assets | $32.86M |
| Fixed Assets | $5.75M |
| Intangible Assets | $7.61M |
| Other Non-current Assets | $19.51M |
| Liabilities | $199.48M |
| Current Liabilities | $117.05M |
| Wages | $13.55M |
| Other Current Liabilities | $103.50M |
| Noncurrent Liabilities | $82.43M |
| Long-term Debt | $72.28M |
| Other Non-current Liabilities | $10.15M |
| Equity | $335.08M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $335.08M |
| Liabilities And Equity | $534.56M |
| Net Cash Flow From Operating Activities | -$53.96M |
| Net Cash Flow From Operating Activities, Continuing | -$53.96M |
| Net Cash Flow From Investing Activities | -$150.96M |
| Net Cash Flow From Investing Activities, Continuing | -$150.96M |
| Net Cash Flow From Financing Activities | $144.00M |
| Net Cash Flow From Financing Activities, Continuing | $144.00M |
| Net Cash Flow | -$60.92M |
| Net Cash Flow, Continuing | -$60.92M |
| Comprehensive Income/Loss | -$81.22M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$81.22M |
| Other Comprehensive Income/Loss | $34.34M |